Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States
Maya Kay
Sagol Department of Neurobiology, University of Haifa, Haifa, Israel
Johann du Hoffmann
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States
Matthew E Klein
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, United States
Ozlem Bozdagi-Gunal
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States
Mohammed Riad
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States
Nikolaos P Daskalakis
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States
Sankalp Sonar
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States
Pablo E Castillo
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, United States
Patrick R Hof
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, United States
Matthew L Shapiro
Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, United States
Mark G Baxter
Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, United States
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States; The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, United States
Mutations in the synaptic gene SHANK3 lead to a neurodevelopmental disorder known as Phelan-McDermid syndrome (PMS). PMS is a relatively common monogenic and highly penetrant cause of autism spectrum disorder (ASD) and intellectual disability (ID), and frequently presents with attention deficits. The underlying neurobiology of PMS is not fully known and pharmacological treatments for core symptoms do not exist. Here, we report the production and characterization of a Shank3-deficient rat model of PMS, with a genetic alteration similar to a human SHANK3 mutation. We show that Shank3-deficient rats exhibit impaired long-term social recognition memory and attention, and reduced synaptic plasticity in the hippocampal-medial prefrontal cortex pathway. These deficits were attenuated with oxytocin treatment. The effect of oxytocin on reversing non-social attention deficits is a particularly novel finding, and the results implicate an oxytocinergic contribution in this genetically defined subtype of ASD and ID, suggesting an individualized therapeutic approach for PMS.